Novartis Cosentyx meets primary and all secondary endpoints in phase III trial in patients with polymyalgia rheumatica: Basel Thursday, October 23, 2025, 09:00 Hrs [IST] Novartis ...
Novartis' Cosentyx Phase 3 REPLENISH trial for polymyalgia rheumatica met primary and secondary endpoints, showing ...
Data highlight potential of Cosentyx as novel targeted PMR treatment, second most common inflammatory disease in adults ≥502, with limited options available ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback